This is a Phase 3 study designed to test whether drug product will slow disease progression in patients with mild memory problems (prodromal Alzheimer's disease)

To assess the hypothesis that solanezumab 400 mg Q4W will slow the clinical progression of prodromal AD over 24 months compared to placebo